donate now The Fatty Liver Foundation

Fatty Liver Foundation Presents Five-Years of U.S. Patient Care Survey Findings at AASLD The Liver Meeting® 2026

Cross-sectional study spanning 2022–2026 reveals a widening mental health gap, modest medication uptake following the first approved MASH therapy, and persistent unmet needs among Americans living with steatotic liver disease

November 5, 2026, Boise, IDAHO - The Fatty Liver Foundation (FLF) will present findings from its State of Steatotic Liver Care in America: 2022–2026 Patient Perspectives Research at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, Colorado. The abstract, titled "Persistent Care Gaps in Patient-Reported Steatotic Liver Disease Experience Across Five National Surveys (2022-2026), Despite the Arrival of MASH-Specific Therapies”, will be presented as part of the MASLD/MASH - Epidemiology and Natural History, Prevention and Outcomes poster session on Friday, November 6, 2026 from 8:00 AM to 5:00 PM at the Colorado Convention Center.

 

Now in its fifth year, this national initiative offers a cross-sectional snapshot of the patient experience as the steatotic liver disease (SLD) landscape itself has shifted. The survey captures the full spectrum of steatotic liver diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD). A record 1,285 adults living with SLD across the US participated in the 2026 survey alone, nearly double the original 2022 sample of 713.

Key Findings From Five Years of Data

  • Clinical practice is moving. Patient experience is not keeping pace. Liver biopsy use declined from 2023 onward, reflecting the growing adoption of noninvasive diagnostic tools. In 2024, the first MASH-specific pharmacologic therapy received FDA approval, a landmark moment for the field, yet patient-reported medication offering increased only modestly in the years that followed. Because the survey captures patients across the full SLD spectrum, not all respondents were candidates for the new therapy. Even accounting for this, the data suggest meaningful gaps in awareness, prescribing, and access that the clinical community has yet to fully bridge.

  • The mental health burden has been carried alone. Across each of the five survey years, more than half of respondents reported experiencing anxiety or depression. Mental health support was offered to fewer than 1 in 10 respondents between 2024 and 2026 while reported sleep quality remained low.

  • Unmet needs have stayed the same, even as the patient community has grown. In 2022, respondents reported a need for peer support, disease-specific education, nutritional guidance, and greater physician empathy. In 2026, with a cohort nearly twice as large, the answers were consistent. 

  • The population most affected is among the most economically vulnerable. By 2026, over half of survey respondents were outside the active workforce (retired or on disability) and over 40% reported a household income under $35,000. Public insurance utilization rose from 2022 to 2026. As new therapies enter the market and specialists remain unevenly distributed across the country, these trends raise serious questions about who will and will not have access to the advances the field is making.

  • ALD and MetALD remain a blind spot. Patients with ALD and MetALD continue to be underrepresented in the survey relative to their estimated prevalence, a pattern that likely reflects broader challenges in capturing these populations, including diagnostic barriers, stigma, and the absence of standardized biomarkers. Reaching these communities more effectively remains a priority for future survey years. 

“Five years of listening to patients tells me the science is finally moving, but the care isn't keeping up. More than half of the people we surveyed live with anxiety or depression, and fewer than one in ten were offered any help with it. A lot of them are retired, disabled, or getting by on under $35,000 a year. A new drug doesn't help anyone it can't reach, so the job now is making sure the people who need it most aren't left standing at the door,” said Wayne Eskridge, Co-Founder and CEO of FLF. 

"What stands out to me is that patients keep telling us the same things, year after year. They want to be heard, they want someone to explain what is happening to them, and they want to know they are not facing this alone," said Henry E. Chang, Executive Director of FLF. "That is why we will keep growing this survey, reach the communities we have not heard from enough, including people living with ALD and MetALD, and make it available in the languages our community speaks."

Tiffany Mensah, FLF’s Patient Engagement and Digital Strategy Manager, added, “I have been part of this survey for five years, and I read the open-ended comments every year. The numbers show us the pattern, but the comments are where you feel it. People write about being tired, being worried, and wanting someone to ask how they are really doing. I hope this poster helps clinicians hear that too, and that these findings move us toward care that treats the whole person.”

“The survey has consistently revealed the importance of managing patients as whole people, and not just medical conditions. Care, support, lifestyle, and diet are some of  the enabling factors that complement medical treatment, and the move toward multidisciplinary teams offers hope to close that gap in care,” noted Dr. Neeraj Mistry, FLF’s Chief Medical Officer. 

 

About the Fatty Liver Foundation

Established in 2017, the Fatty Liver Foundation (FLF) is a national non-profit organization dedicated to improving the identification, diagnosis, treatment, and support of people living with the entire spectrum of steatotic liver disease (SLD), including MASLD, MASH, MetALD, and ALD. Through awareness, screening, education, and patient engagement, FLF works to improve outcomes for both asymptomatic and diagnosed individuals while advancing equitable access to care and early detection.

FLF also leads Sober Livers, an impact program providing education and peer support for people living with MetALD, ALD, and alcohol use disorder (AUD). Together, these initiatives embody FLF’s mission to empower patients, raise awareness, and strengthen health systems to respond to the growing epidemic of liver disease.

Connect with us at www.fattyliverfoundation.org, on Facebook (Fatty Liver Foundation JUST LIVER NEWS), LinkedIn (Fatty Liver Foundation), X/Twitter (@LiverSaver), and YouTube (Fatty Liver Foundation). 

 

MEDIA CONTACT

Henry E. Chang

Executive Director

Fatty Liver Foundation

Email: [email protected]

Phone: +1 917 400-8900

 

#   #   #

 

connect